Adiponectin is also considered a good marker for predicting severity of non-alcoholic fatty liver disease and recent therapeutic approaches have been focused on indirectly increasing adiponectin levels [37]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.